Medicsight PLC (AIM: MDST), an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, today announces the signing of an exclusive CAD clinical research  agreement with leading US CT Colonography radiologists, Dr. Perry Pickhardt and Dr. David Kim, from the University of Wisconsin Medical School, Madison, WI.

Dr Pickhardt, Associate Professor of Radiology and Dr Kim along with The University of Wisconsin were the first group to establish a third-party reimbursed CT colonography colorectal cancer screening programme in 2004.  Since then they have both played an instrumental role in building the clinical evidence base that has proven the comparable effectiveness of CTC for the detection of colorectal neoplasia within an asymptomatic population in relation to Optical Colonoscopy.  A key milestone recently achieved, partly as a result of their research, was the release of the American Cancer Society 2008 Consensus Guidelines that focus on colon cancer prevention and for the first time have recommended CTC be provided every five years for adults aged 50 years and over.

Commenting on the collaboration, Dr. Perry Pickhardt said "Dr. Kim and I are excited about the Medicsight CAD research collaboration.  This work promises to further improve the clinical performance of CAD and help define its role within colon cancer screening programmes in the USA"

David Sumner, CEO of Medicsight, commented "I am delighted that Perry Pickhardt and David Kim, global leaders in CTC and radiology, have entered into this exclusive research agreement with Medicsight.  Their specialist advice and vast experience of CTC practice will greatly enhance the clinical validation of Medicsight's ColonCAD products set in the context of the world's largest healthcare market.  As a company we underpin all our efforts with best of breed clinical research.  This research partnership clearly demonstrates this fact to both our partners and their customers alike".

For further information:
Medicsight plc
David Sumner, CEO +44 (0)20 7605 7950
www.medicsight.com

Nomura Code Securities Limited
Juliet Thompson, Managing Director +44 (0)20 777 61200
Jon Senior www.nomuracode.com

Media enquiries:

Abchurch Tel: +44 (0) 20 7398 7700
Heather Salmond Tel: +44 (0) 20 7398 7704
Stephanie Cuthbert / Simone Alves Tel: +44 (0) 20 7398 7718
stephanie.cuthbert@abchurch-group.com
www.abchurch-group.com

Notes to editors
Medicsight PLC is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD™ and LungCAD™ software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 1000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This is critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome.

About Medicsight's CAD software
Medicsight's ColonCAD™ and LungCAD™ software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.